The design of drugs for HIV and HCV

  title={The design of drugs for HIV and HCV},
  author={Erik De Clercq},
  journal={Nature Reviews Drug Discovery},
  • E. Clercq
  • Published 1 December 2007
  • Biology, Medicine
  • Nature Reviews Drug Discovery
Since the discovery of the human immunodeficiency virus (HIV) in 1983, dramatic progress has been made in the development of novel antiviral drugs. The HIV epidemic fuelled the development of new antiviral drug classes, which are now combined to provide highly active antiretroviral therapies. The need for the treatment of hepatitis C virus (HCV), which was discovered in 1989, has also provided considerable impetus for the development of new classes of antiviral drugs, and future treatment… 

Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs.

Ongoing efforts are focused on improvement of potency, selectivity and delivery of antiviral nucleoside analogues, with several recent promising advances into clinical trials.

Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus

There are beneficial aspects in the response of the scientific community to the HIV burden for the management of other viral diseases and these aspects are described in this contribution.

Emerging drugs for hepatitis C

Combination therapy with a backbone of pegIFN/RBV, or perhaps in the future using several of these small molecules, preferably having distinct modes of action and resistance profiles, will be required.

Inhibition of HIV-1 replication by RNA-based strategies.

This review describes the main features and functions of viral and cellular targets as well as the different classes of RNA molecules that have been explored in developing therapeutic strategies against HIV infection.

Antivirals: current state of the art

Most of the antiviral agents that have been approved, and are currently used in the treatment of virus infections, are targeted at HIV, HBV, herpes simplex virus (HSV), varicella-zoster virus (VZV),

Potent Inhibition of HIV‐1 Entry with a Chemically Programmed Antibody Aided by an Efficient Organocatalytic Synthesis

This work chemically programmed an antibody using a small molecule drug that targets the CCR5 G protein-coupled receptor, and designed a derivative of Aplaviroc that allows for its attachment to the active site of cpAb while maintaining C CR5 binding, which displays an intriguing pharmacology that might allow for the potential of the chemically programmed antibody approach to correct pharmacological issues of small molecules.

Antiviral Chemistry & Chemotherapy's Current Antiviral Agents FactFile 2008 (2nd Edition): RNA Viruses

For HCV infections, standard treatment consists of the combination of pegylated interferon-α with ribavirin, but several other antivirals targeted at specific viral functions such as the HCV protease and/or polymerase may be expected to soon take an important share of this important market.

Antiviral therapy: old and current issues.

Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV.

For the first time, it is reported that ribavirin is efficacious in fighting HIV and in the form of MP, the treatment is safe, both in terms of lack of association of Ribavirin with red blood cells and lack of toxicity upon cellular internalization.

Outlook of the Antiviral Drug Era, Now More Than 50 Years After Description of the First Antiviral Drug

IDU, soon to be followed by TFT (trifluorothymidine), could be considered as the third, and successful, attempt to herald the antiviral chemotherapy era.



Strategies in the design of antiviral drugs

  • E. Clercq
  • Biology, Medicine
    Nature Reviews Drug Discovery
  • 2002
The rationale behind current and future drug-based strategies for combating viral infections and the need for further refinement of antiviral drug design and development is described.

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.

  • R. Pauwels
  • Biology
    Current opinion in pharmacology
  • 2004

Review HCV Antiviral Resistance: The Impact of in vitro Studies on the Development of Antiviral Agents Targeting the Viral NS5B Polymerase

HCV sub-genomic replicons have been used to study viral resistance to both nucleoside and non-nucleoside NS5B inhibitors and suggest that drug-resistant viruses are likely to evolve in vivo.

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

This work describes the discovery and development of enfuvirtide (Fuzeon), the first drug to inhibit the entry of HIV-1 into host cells, and the growing problem of the emergence of HIV strains that are resistant not only to individual drugs, but to whole drug classes.

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor, illustrating the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.

Hepatitis C therapeutics: current status and emerging strategies

The development of effective HCV antiviral therapeutics continues to be a daunting challenge owing to the absence of adequate animal models and tissue-culture systems for analysis and propagation of the virus.

Antiviral agents active against influenza A viruses

Key PointsSeveral drugs are available that could be used, either alone or in combination, for the treatment (prophylaxis or therapy) of an influenza pandemic. These include adamantan(amin)e

Challenges and successes in developing new therapies for hepatitis C

Preclinical evidence is accumulating that development of resistance will eventually limit the efficacy of new drugs, and combinations of multiple agents will be required to treat chronic HCV infection.

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

The combination of VX-950 and alpha interferon was additive to moderately synergistic in reducing HCV RNA in replicon cells with no significant increase in cytotoxicity and the benefit of the combination was sustained over time.

Anti-HIV drugs.

Given the information that has been acquired on the therapeutic use (efficacy, safety) of tenofovir disoproxil fumarate over the past five years, it would now seem mandatory to further consider the prophylactic use of TDF [and its combination with emtricitabine] as a single daily pill to prevent HIV infection.